Free shipping starts now, no minimum, no coupons required!

Anti-proNGF Antibody

Nerve growth factor precursor

Cat #: ANT-005
Alternative Name Nerve growth factor precursor
Lyophilized Powder yes
Type: Polyclonal
Host: Rabbit
Reactivity: h, m, r
  • Peptide (C)SPRVLFSTQPPPTSSDTLDLD, corresponding to amino acid residues 84-104 of rat NGF (precursor) (Accession P25427). Pro-domain of the NGF protein.
Accession (Uniprot) Number P25427
Gene ID 310738
Peptide confirmation Confirmed by amino acid analysis and mass spectrometry.
Homology Mouse - identical; human - 16/21 amino acid residues identical.
RRID AB_2040021.
Purity Affinity purified on immobilized antigen.
Form Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.
Isotype Rabbit IgG.
Specificity The antibody is specific for proNGF, it does not crossreact with proBDNF, proNT-3 or mature NGF.
Storage before reconstitution The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.
Reconstitution 25 µl, 50 μl or 0.2 ml double distilled water (DDW), depending on the sample size.
Antibody concentration after reconstitution 0.8 mg/ml.
Storage after reconstitution The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).
Standard quality control of each lot Western blot analysis.
Applications: if, ih, wb
May also work in: ic*, ifc*, ip*
Western blot
  • Western blot analysis of Recombinant mouse proNGF protein (#N-250), (lanes 1-3) and Recombinant human proNGF protein (#N-280), (lanes 4-6):
    Western blot analysis of Recombinant mouse proNGF protein (#N-250), (lanes 1-3) and Recombinant human proNGF protein (#N-280), (lanes 4-6):
    1,4. 100 ng + Anti-proNGF Antibody (ANT-005), (1:200).
    2,5. 250 ng + Anti-proNGF Antibody (1:200).
    3,6. 500 ng + Anti-proNGF Antibody (1:200).
  • Western blot analysis of mouse submandibular glands (SMGs):
    Western blot analysis of mouse submandibular glands (SMGs):
    1. Anti-proNGF Antibody (#ANT-005), (1:200).
    2. Anti-proNGF Antibody, preincubated with proNGF Blocking Peptide (#BLP-NT005).
  • Expression of proNGF in rat brain sections
    Expression of proNGF in rat brain sections
    Immunohistochemical staining of proNGF in rat brain sections using Anti-proNGF Antibody (#ANT-005). A. Staining of astrocytes was performed using mouse anti-glial fibrillary acidic protein (GFAP) (red). B. Co-localization between GFAP and proNGF (orange). C. Staining of proNGF (green).
  1. Lessman, V. et al. (2003) Prog. Neurobiol. 69, 341.
  2. Bibel, M. and Barde, Y.A. et al. (2000) Genes Dev. 14, 2929.
  3. Lee, R. et al. (2001) Science 294, 1945.
  4. Ibanez, C.F. (2002) Trends Neurosci. 25, 284.
  5. Hasan, W. et al. (2003) J. Neurobiol. 57, 38.
  6. Beattie, M.S. et al. (2002) Neuron 36, 375.
  7. Fahnestock, M. et al. (2001) Mol. Cell. Neurosci. 18, 210.
  8. Lu, B. (2003) Neuron 39, 735.
Scientific background

Neurotrophins are synthesized as pro-forms that can be cleaved either intracellularly to release mature, secreted ligands, or extracellularly by various proteases such as plasmin, furin, PC1/3, PC7, and PACE 4.1,2,5 The immature precursor has a prodomain of 103 amino acids, which was thought to have a role in the folding and sorting of the mature NGF into the various secretion pathways. 

It was recently reported that proNGF, binds p75NTR receptor preferentially over TrkA, and this selective binding of proNGF to p75NTR  leads to apoptotic death of cells that express both TrkA and p75NTR. However, mature NGF binds and activates both receptors, with resulting promotion of cell survival due to the TrkA-mediated survival signal overriding p75NTR -mediated apoptotic signal.3,4 

Since pro- and mature neurotrophins seem to elicit opposite functional effects, by differential interactions with Trks and p75NTR receptors, extracellular cleavage represents a new way to control the synaptic functions of neurotrophins.

It was demonstrated that proNGF from injured spinal cord extracts, is active and induce apoptosis among oligodendrocytes, and apoptosis can be blocked by a proNGF-specific antibody.6  

Finally, proNGF was demonstrated as the predominant form in mouse, rat, and human brain tissue, thyroid, hippocampus, thus suggesting a role for proNGF in vivo.5,7,8

Application key:

CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot

Species reactivity key:

H- Human, M- Mouse, R- Rat
Last update: 08/01/2023

Alomone Labs is pleased to offer a highly specific antibody directed against rat proNGF. Anti-proNGF Antibody (#ANT-005) can be used in western blot and immunohistochemical applications. The antibody specifically reacts with proNGF. It has been designed to recognize proNGF from mouse, rat and human samples.

Related products for neutralizing proNGF activity:
Mouse NGF/proNGF Neutralizing Antibody (#ALM-006) can be used in indirect ELISA and neutralization assays to block the biological effects of both NGF and proNGF.

For research purposes only, not for human use



Western blot citations
  1. Rat microglia and spinal cord lysates (1:200).
    Jung, G.Y. et al. (2013) Glia 61, 1807.
  2. Mouse retina lysate.
    Mysona, B.A. et al. (2013) Diabetologia 56, 2329.
Immunohistochemistry citations
  1. Mouse retina sections (1:100).
    Mysona, B.A. et al. (2013) Diabetologia 56, 2329.
More product citations
  1. Matragoon, S. et al. (2012) Mol. Vis. 18, 2993.
  2. Peleshok, J.C. and Ribeiro da Silva, A. (2012) Mol. Pain 8, 1.
  3. Shulga, A. et al. (2012) J. Neurosci. 32, 1757.
  4. Al-Gayyar, M.M. et al. (2011) Diabetologia 54, 669.
  5. Spinnler, K. et al. (2011) J. Biol. Chem. 286, 31707.
  6. Weinstock, M. et al. (2011) Neurobiol. Aging 32, 1069.
  7. Ali, T.K. et al. (2011) Diabetologia 54, 657.
  8. Al-Shawi, R. et al. (2008) Eur. J. Neurosci. 27, 2103.
  9. Watanabe, T. et al. (2008) J. Neurosci. Res. 86, 3566.
  10. Yune, T.Y. et al. (2007) J. Neurosci. 27, 7751.
  11. Bruno, M.A. and Cuello, C.A. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 6735.


Scientific Background

Shipping and Ordering information